Targeted inactivation of PPP6C, via CRISPR-Cas9, in HSPCs derived from normal donors and SCD patients resulted in increased levels of HbF, measured by HPLC, and reversal of SCD phenotype [169] (Table S2). Here, PPP6C is linked to Schnyder corneal dystrophy.